sodium (3-bromophenyl)methanesulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sodium (3-bromophenyl)methanesulfonate
• 英文别名: Sodium;(3-bromophenyl)methanesulfonate；sodium;(3-bromophenyl)methanesulfonate
• 化学式: C₇H₆BrO₃S*Na
• 分子量: 273.083
• InChiKey: QFJDDENHAIVGRR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  sodium (3-bromophenyl)methanesulfonate 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 3-溴苄基磺酰氯
  参考文献：
  名称：

  TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE

  摘要：

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制5-脂氧合酶（5-LO）的活性。本文还描述了使用这种5-LO抑制剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的状况、疾病或紊乱。

  公开号：

  US20070173508A1
• 作为产物：
  描述：

  3-溴苄溴 在 sodium sulfite 作用下， 以 乙醇 、 水 为溶剂， 生成 sodium (3-bromophenyl)methanesulfonate
  参考文献：
  名称：

  TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE

  摘要：

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制5-脂氧合酶（5-LO）的活性。本文还描述了使用这种5-LO抑制剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的状况、疾病或紊乱。

  公开号：

  US20070173508A1

文献信息

• Synthesis of α-Fluorosulfonamides by Electrophilic Fluorination
  作者：Bryan Hill、Yong Liu、Scott D. Taylor

  DOI：10.1021/ol048249z

  日期：2004.11.1

  alpha-Fluorosulfonamides were prepared by electrophilic fluorination of tertiary sulfonamides using N-fluorobenzenesulfonimide as fluorinating agent and utilizing the dimethoxybenzyl group (DMB) as a new sulfonamide protecting group. Removal of the DMB group with TFA/CH2Cl2 gave primary and secondary alpha-fluorosulfonamides.
• Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands
  作者：Masoud Sadeghzadeh、Shahab Sheibani、Mehdi Ghandi、Fariba Johari Daha、Massoud Amanlou、Mohammad Arjmand、Abolfazl Hasani Bozcheloie

  DOI：10.1016/j.ejmech.2013.04.013

  日期：2013.6

  This study presents the synthesis and biological evaluation of a new series of arylalkyliary/alkylsulfonyl piperazine and piperidine-based derivatives as sigma receptor ligands. It was found that a number of halogen substituted sulfonamides display relatively high and low affinities to sigma(1) and sigma(2) receptors, respectively. The sigma(1) affinities and subtype selectivities of four piperidine derivatives were also found to be generally comparable to those of piperazine analogues. Compared to sigma(1)-Rs compounds with n = 0 and 2, those with n = 1 proved to have optimal length of carbon chain by exhibiting higher affinities.Within this series, the 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine sigma ligand was identified with 96-fold sigma(1)/sigma(2) selectivity ratio (K-i sigma(i) = 0.96 +/- 0.05 nM and K-i sigma(2) = 91.8 +/- 8.1 nM). (C) 2013 Elsevier Masson SAS. All rights reserved.
• The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors
  作者：Carmen Leung、Justyna Grzyb、Jason Lee、Natalie Meyer、Gabriel Hum、Chenguo Jia、Shifeng Liu、Scott D Taylor

  DOI：10.1016/s0968-0896(02)00062-7

  日期：2002.7

  Three peptides, 7-9, bearing sulfono(difluoromethyl)phenylalanine (F(2)Smp,2), a nonhydrolyzable, monoanionic phosphotyrosine mimetic, were prepared and evaluated as PTP1B inhibitors. The most effective inhibitor was the nonapeptide. ELEF(F(2)Smp)MDYE-NH2. (9) which exhibited a K-i of 360 nM. A comparison of F-2-Smp-bearing peptides 7 [DADE(F(2)Smp)LNH2. K-i=3.4 muM] and 8 [EEDE(F(2)Smp)LNH2. K-i=0.74 muM] with their phosphono(difluoromethyl)phenylalanine (F(2)Pmp)-bearing analogues indicated that F(2)Smp is not as effective a pTyr mimetic as F(2)Pmp by 100- to 130-fold. Although F(2)Smp is not as effective as F(2)Pmp, a comparison of peptide 7 with analagous peptides bearing other monoanionic pTyr mimetics recently reported in the literature indicates that F(2)Smp is about 65-fold more effective than any other non-hydrolyzable, monanionic pTyr mimetic reported to date. To further assess the difluoromethylenesulfonic acid (DFMS) group as a monoanionic phosphate mimetic, a series of 24 nonpeptidyl biaryl compounds bearing the DFMS group were prepared using polymer-supported methodologies and screened for PTP 1B inhibition. Several of these compounds were selected for further study and their IC50's compared to their difluoromethylenephosphonic (DFMP) analogues. The differences in IC50's between the DFMS and DFMP non-peptidyl compounds was not as great as with the F(2)Smp- and F(2)Pmp-bearing peptides. Possible reasons for this and its implication to the design of small molecule PTP1B inhibitors is discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.
• 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS
  申请人：Wyeth LLC

  公开号：EP2229377A1

  公开（公告）日：2010-09-22
• [EN] 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS<br/>[FR] 5-ALKYL/ALCÉNYL-3-CYANOPYRIDINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：WYETH CORP

  公开号：WO2009076602A1

  公开（公告）日：2009-06-18

  Described herein are compounds of formula I: wherein G is and pharmaceutically acceptable salts thereof, wherein J, X, R1, R2, R11, R12' and p are as defined herein. Also provided herein are methods of making the compounds of formula I, and methods of using these compounds for inhibiting or treating a pathological condition or disorder linked to or mediated by a protein kinase in a mammal.